Development and charecterization of PLGA - nanoparticles containing carvedilol

The objective of this study was to prepare PLGA nanoparticles of Carvedilol that will improve the bioavailability of Carvedilol and sustain the release to reduce the initial hypotensive peak and to prolong the antihypertensive effect of the drug. Carvedilol encapsulated by Nanoprecipitation method using PLGA and Pluronic F-68.Prepared nanoparticles were examined for physicochemical characteristics, in vitro release kinetics and invivo biodistribution studies. Average size of the nanoparticles were in range of 132-234nm. The drug encapsulation efficiency was 77.6% at 33% drug loading. In vitro cumulative release from the nanoparticles was 72% at 24hr. In vivo biodistribution studies in rats revealed that these particles are distributed in heart, liver and kidney at higher concentration may allow their delivery to target sites.